Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer
Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.
Dr. Jhaveri on T-DM1 in the Neoadjuvant Setting
Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
2 Clarke Drive Cranbury, NJ 08512